Your browser doesn't support javascript.
loading
Predictive validity of Lupus Patient-Reported Outcome for damage accrual in patients with systemic lupus erythematosus: the LUNA Registry.
Nose, Yoko; Onishi, Akira; Nishimura, Keisuke; Yamamoto, Yuzuru; Sada, Ken-Ei; Ichinose, Kunihiro; Yoshimi, Ryusuke; Ohno, Shigeru; Yanai, Ryo; Kajiyama, Hiroshi; Sato, Shuzo; Shimojima, Yasuhiro; Fujiwara, Michio; Kida, Takashi; Miyawaki, Yoshia; Matsuo, Yusuke; Tsuji, Hideaki; Morinobu, Akio; Saegusa, Jun.
Afiliação
  • Nose Y; Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Onishi A; Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Nishimura K; Department of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Yamamoto Y; Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Sada KE; Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Ichinose K; Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan.
  • Yoshimi R; Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Ohno S; Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Yanai R; Department of Rheumatology, Shimane University Faculty of Medicine, Izumo, Japan.
  • Kajiyama H; Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Sato S; Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan.
  • Shimojima Y; Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan.
  • Fujiwara M; Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Kida T; Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
  • Miyawaki Y; Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Matsuo Y; Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
  • Tsuji H; Department of Rheumatology, Yokohama Rosai Hospital, Yokohama, Japan.
  • Morinobu A; Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Saegusa J; Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and pharmaceutical Sciences, Okayama University, Okayama, Japan.
Article em En | MEDLINE | ID: mdl-38885408
ABSTRACT

OBJECTIVES:

The predictive validity of disease-specific quality of life (QOL) remains unknown in patients with systemic lupus erythematosus (SLE), although disease-specific measures are equally or more responsive to changes than generic QOL. We aimed to examine the predictive validity of the Lupus patient-reported outcome (PRO) for damage accrual.

METHODS:

Patients with SLE and ≥2 measurements over time were included in Japanese nationwide multicentre registry (LUNA). The Lupus PRO questionnaire contains both health-related (HR) and non-HR-QOL measures. Damage accrual was evaluated using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We examined the association between the Lupus-PRO score at baseline and longitudinal SDI scores using mixed-effects models adjusted for prognostic factors.

RESULTS:

Among 1295 patients, those with higher HR-QOL of Lupus PRO at baseline demonstrated a significantly lower increase in SDI (-0.005/year, 95% confidence interval [CI] -0.007 to - 0.004, p < 0.001). According to the categorisation of HR-QOL based on tertile, a similar dose-dependent effect of HR-QOL on longitudinal SDI was identified (second vs first tertile category -0.101/year, 95% CI -0.172 to - 0.030; third tertile category -0.211/year, 95% CI -0.281 to - 0.142). Non-HR-QOL was not significantly associated with the SDI scores. Among the HR-QOL domains, cognition, procreation, and physical health were significantly associated with the total SDI scores over time. HR-QOL was associated with corticosteroid-dependent and -independent SDI scores.

CONCLUSION:

A higher HR-QOL of Lupus PRO was associated with a lower increase in SDI scores. Our findings imply the importance of disease-specific HR-QOL measurements in assessing prognosis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão